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Abstract The cellular and molecular mechanisms of
tumor angiogenesis and its prospects for anti-angiogenic
cancer therapy are major issues in almost all current
concepts of both cancer biology and targeted cancer ther-
apy. Currently, (1) sprouting angiogenesis, (2) vascular
co-option, (3) vascular intussusception, (4) vasculogenic
mimicry, (5) bone marrow-derived vasculogenesis,
(6) cancer stem-like cell-derived vasculogenesis and
(7) myeloid cell-driven angiogenesis are all considered to
contribute to tumor angiogenesis. Many of these processes
have been described in developmental angiogenesis; how-
ever, the relative contribution and relevance of these in
human brain cancer remain unclear. Preclinical tumor
models support a role for sprouting angiogenesis, vascular
co-option and myeloid cell-derived angiogenesis in glioma
vascularization, whereas a role for the other four mecha-
nisms remains controversial and rather enigmatic. The anti-
angiogenesis drug Avastin (Bevacizumab), which targets
VEGF, has become one of the most popular cancer drugs in
the world. Anti-angiogenic therapy may lead to vascular
normalization and as such facilitate conventional cytotoxic
chemotherapy. However, preclinical and clinical studies
suggest that anti-VEGF therapy using bevacizumab may
also lead to a pro-migratory phenotype in therapy resistant
glioblastomas and thus actively promote tumor invasion
and recurrent tumor growth. This review focusses on
(1) mechanisms of tumor angiogenesis in human malignant
glioma that are of particular relevance for targeted therapy
and (2) controversial issues in tumor angiogenesis such as
cancer stem-like cell-derived vasculogenesis and bone-
marrow-derived vasculogenesis.
Introduction
In his landmark 1971 publication, Folkman [41] developed
the idea that tumor growth is angiogenesis dependent and
described for the ﬁrst time the potential prospects of anti-
angiogenic cancer therapy. From thereon, it took 13 years
before ﬁbroblast growth factor (FGF)-2, the ﬁrst heparin-
binding angiogenic growth factor, was identiﬁed and
18 years before vascular endothelial growth factor
(VEGF), which by now has turned out to be the single most
important angiogenesis factor in both health and disease,
was described (for review see [38]). Napoleone Ferrara,
one of the discoverers of VEGF, developed monoclonal
antibodies to VEGF [70] that blocked tumor growth in vivo
[71] and that paved the way for the development of bev-
acizumab, a monoclonal anti-VEGF antibody that is now
used in a large number of clinical cancer trials, including
glioblastoma, where anti-angiogenesis represents one
treatment arm [104, 131]. It is now evident that the entire
process of tumor-induced angiogenesis appears to be far
more complex than initially envisioned [15]. Moreover, the
idea that blockade of tumor angiogenesis is able to inhibit
tumor growth in vivo has been conﬁrmed in principal in
both experimental and clinical settings; however, current
evidence suggests that cancer cells are able to circumvent
anti-angiogenic therapy and develop resistance to targeted
mono-therapy [7, 129].
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In a recent Cell snapshot Jain and Carmeliet listed six
different principal cellular mechanisms under the heading
of tumor angiogenesis. These include (1) classical sprout-
ing angiogenesis, (2) vascular co-option, (3) vessel
intussusception, (4) vasculogenic mimicry, (5) bone mar-
row derived vasculogenesis and (6) cancer stem-like cell
derived vasculogenesis [62]. Another important mecha-
nism of tumor angiogenesis is angiogenesis driven by
blood derived inﬁltrating myeloid cells, a process that
recently received considerable attention. Whether the
above listed mechanisms of tumor angiogenesis (for
overview see Fig. 1) are all operational in human glio-
blastoma is not entirely clear. Here, we brieﬂy discuss the
above mentioned angiogenesis mechanisms and review the
existing evidence for their role in glioma biology.
Angiogenesis, the sprouting of capillaries from pre-
existing vessels, has since long been considered the prin-
cipal mechanism of brain vascularization, both during
development and in brain cancer [80, 81, 111, 121].
A vascular sprout that is led by a ﬁlopodia-rich tip cell
migrates toward an angiogenic stimulus (often VEGF) that
is produced by tumor cells. Following the tip are a group of
cells, entitled stalk cells, that divide, which promotes the
elongation of the sprout (Fig. 2). Tip cells from two dis-
tinct sprouts may fuse to yield a larger sprout, a process
that is thought to be modulated by the action of macro-
phages on these activated endothelial cells (Fig. 4).
Thereafter, the newly formed vessel remodels to form a
vascular lumen (that permits blood ﬂow) and to attract
mural cells that stabilize the vessel (reviewed in [16, 143]).
Current evidence suggests that vascular sprouting repre-
sents a major mechanism of tumor angiogenesis. Analysis
of cell division in glioblastoma, by MIB-1 staining, sug-
gests that there are a considerable number of vascular
endothelial cells undergo cell division suggesting that these
cells may represent stalk cells. In addition to this, mole-
cules typically expressed on endothelial tip cells such
as VEGFR-2, Neuropilin-1, Angiopoietin-2 (Ang-2), Inte-
grin-ß1 and others have been described to be present in
glioma vessels in situ [11, 31, 114], implying that tip
and stalk cell phenotypes co-exist in the glioblastoma
vasculature.
Fig. 1 Potential mechanisms of glioma angiogenesis. Currently, (1)
sprouting angiogenesis, (2) vascular co-option, (3) vascular intussu-
secption, (4) vasculogenic mimicry, (5) bone marrow-derived
vasculogenesis, (6) cancer stem-like cell derived vasculogenesis and
(7) myeloid cell-driven angiogenesis are all considered to contribute
to tumor angiogenesis. However, some of these mechanisms have
initially been described in developmental angiogenesis and their
relative contribution and relevance in human brain cancer is unclear
(see text)
764 Acta Neuropathol (2012) 124:763–775
123Vascular co-option describes the inﬁltration of tumor
cells into normal tissue and the adoption of the pre-existing
vasculature [56]. When one takes this into consideration,
vascular co-option may be viewed as part of the invasive
phenotype that is intrinsic to all diffuse gliomas—rather
than an active vascular process. Invoking the process of
vascular co-option aligns well with the known migratory
pattern of tumor cells along vessels which has been
observed in numerous experimental glioma models in
rodents. Vascular co-option may facilitate the inﬁltration of
human gliomas. Of note, anti-VEGF treatment may drive
glioma cells to utilize the co-option pathway thereby cir-
cumventing the impact of anti-VEGF treatment resulting in
an increase in the number of migrating glioma cells, that
may use pre-existing vessels as scaffolds for their migra-
tion pathways (see below).
Vessel intussusception describes the formation of a new
vessel by vascular invagination, intra-luminar pillar for-
mation and splitting. Vascular intussusception has initially
been described in physiological vascular development [32]
but more recently has been expanded to experimental
tumors. It has been suggested that sprouting angiogenesis
may switch to vascular intussusception to allow rapid
development of new vessels [119]. The molecular mecha-
nisms that drive vascular intussusception are currently
poorly understood and whether intussusception occurs or
plays a role in human glioma or tumor biology in general is
currently unclear.
Vasculogenic mimicry is deﬁned as a process where
tumor cells replace endothelial cells and form a vessel with
a lumen This phenomenon was ﬁrst described (mainly
based on PAS staining) in a subset of aggressive uveal
melanomas [95] and later in other types of cancer but its
overall occurrence and signiﬁcance, if any, is highly con-
troversial. Moreover, it is unclear whether vasculogenic
mimicry represents an active process (e.g., cancer cells
actively forming the vascular lumen) or whether vasculo-
genic mimicry is a consequence of vessel regression.
Vessel regression is part of the vascular remodeling process
that takes place in development but can also occur in
tumors (Fig. 2a). During development, a normal and well-
orchestrated realignment of the balance between growth/
survival signals such as high levels of Ang-2 together with
low levels of VEGF leads to vessel regression and endo-
thelial cell apoptosis causing vessel pruning and vessel
remodeling [50]. A similar situation (high levels of Ang-2
combined with low levels of VEGF) can occur in cancer
after bevacizumab therapy and may therefore be respon-
sible for intratumoral vessel regression. In addition to
programmed vessel regression, cessation of blood ﬂow due
to development of shunts or the thrombosis of tumor ves-
sels can lead to tumor vessel regression via down-
regulation of the transcription factor kruppel-like factor2
(KLF2) and subsequent up-regulation of Ang-2 (Fig. 2b)
[74, 145]. McDonald and colleagues have discussed the
phenomenon of vasculogenic mimicry in detail and came
to the conclusion that even in the prototype of cancer that
shows vasculogenic mimicry, aggressive uveal melanomas,
vascular channels are almost always lined by endothelial
cells and not by cancer cells [98, 99], leading these authors
generally doubt the signiﬁcance of vasculogenic mimicry
in tumor angiogenesis. Studies dealing with vasculogenic
mimicry in human gliomas are sparse and mainly rely on
PAS-staining to identify cancer cell-lined vascular chan-
nels. In one study, PAS-positive vascular channels devoid
of CD34? cells have been described in 2/45 human glioma
specimens [155], and in 13 out of 101 samples in another
study [89]. Recently, based on double-immunoﬂuorescence
staining, co-expression of GFAP (a marker for glioma
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Fig. 2 VEGF and Notch regulate tip and stalk cell dynamics during
vascular sprouting. a Angiogenic sprouting is initialized by VEGF
signaling and spatially and temporally regulated by a VEGF gradient
(brown). Endothelial tip cells exhibit numerous ﬁlopodia extensions
sensing the environment for migration cues and are devoid of pericyte
coverage (turquois). b Blowup showing the induction and mainte-
nance of tip versus stalk cell identity. Tip cells are induced by VEGF
(black) that binds to VEGFR2/3 (green) localized on the ﬁlopodia.
VEGF-signaling in tip cells up-regulates Dll4 (black) and Notch1
(blue) ligand. Dll4–Notch signaling will in turn modulate VEGFR2/3
in adjacent cells, thereby inducing the stalk cell phenotype. Further-
more, VEGFR1 (light blue) becomes up-regulated and acts as a
VEGF decoy receptor (shaded circular area) and helps maintaining
the VEGF gradient
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123cells) and VEGFR-2 (a marker for endothelial cells) has
been reported in 7 out of 11 human GBM investigated and
has been considered as evidence for vasculogenic mimicry
[44], but this awaits conﬁrmation. In summary, the func-
tional and clinical relevance of vasculogenic mimicry
appears questionable in light of the methodological prob-
lems encountered. Rather, we prefer to conclude from the
data published that vasculogenic mimicry appears to be of
little signiﬁcance in glioblastoma angiogenesis, since most
vessels appear to be lined by a proper endothelium on the
luminal side.
Bone marrow-derived vasculogenesis describes the
recruitment of circulating endothelial precursor cells to the
tumor, their integration into the vessel wall and their ter-
minal differentiation into an endothelial cell. From the
onset of the original description of tumor vasculogenesis
[2], this phenomenon has attracted a considerable amount
of attention. This attention has stemmed from the fact that
it has challenged the previous dogma that the postnatal
vasculature (under both physiological and pathological
conditions) can only proceed via angiogenesis but not
vasculogenesis in order to adapt to altered physiological
needs [121]. Mouse molecular studies that used chimeric
mice with GFP-tagged bone marrow cells together with
high-resolution confocal imaging and 3D-reconstruction
revealed however that BM-derived endothelial cells in
experimental gliomas represent only a small amount (less
than 1 %) of all vascular endothelial cells [93]. However, it
has been suggested that vasculogenesis is important for
neovascularization after tumor irradiation [72]. Again, this
issue has lead to a controversy since work from several
laboratories suggests that bone marrow-derived cells do not
incorporate into the vessel lumen to a signiﬁcant extent but
rather stay adjacent to the vessel, in a perivascular location
[75]. These results suggest that bone marrow-derived cells
support angiogenesis in a paracrine manner but presumably
not by incorporation into the endothelial cell layer proper
[76]. This imprecise use of the term ‘‘vasculogenesis’’ has
facilitated the confusion in the literature about the process
of tumor vasculogenesis [75]. Taken together, ‘‘real’’ tumor
vasculogenesis appears to be a rare biological event that
probably does not bear any clinical signiﬁcance in human
glioblastoma.
Cancer stem-like cell derived vasculogenesis: In 2010,
two groups independently reported the transdifferentiation
of GBM-derived stem-like cells into endothelial cells
in vitro [120, 148]. The authors showed further that a
proportion of vascular cells within human GBM contained
genetic alterations that are typically encountered in glio-
blastoma cells (such as EGFR ampliﬁcation) and are
typically not seen in vascular endothelial cells. One group
even reported that the majority of GBM vascular cells
contained genetic alterations typically found in tumor cells
[120]. The authors concluded that GBM-derived cancer
stem-like cells can contribute to the vasculature by inte-
grating into the vascular wall and transdifferentiate into
endothelial cells, while retaining their genetic alterations.
In contrast to this, recent work by Rodriguez [123] who
examined GBM by detailed histological analysis demon-
strated that in GBM (1) mutant vascular cells are extremely
rare and (2) these cells are usually found in the perivascular
space or vascular wall but were not lining the vessel lumen.
Taken together, the existence of cancer stem-like cell-
derived vasculogenesis in human glioblastoma is highly
controversial and at best appears to be a very rare event.
The participation of bone marrow derived cells in
driving tumor angiogenesis has achieved considerable
attention recently (for reviews see [47, 66]). In particular,
monocytes/macrophages can polarize into phenotypes that
exert different functions in vivo. In contrast to M1 mono-
cytes/macrophages, that are anti-tumorigenic, M2-
polarized monocytes/macrophages are pro-angiogenic and
thus drive tumor growth [135]. Current evidence suggests
that monocytes/macrophages secrete a variety of pro-
tumorigenic and pro-angiogenic growth factors (including
VEGF). Experimental studies in glioma models suggest
that blocking of monocyte/macrophage recruitment and/or
function may block glioma growth (see below). As such,
monocytes/macrophages represent an attractive target for
anti-angiogenic tumor therapy although the relevance of
bone marrow driven angiogenesis in human glioma still
needs to be determined.
Angiogenic signaling pathways in glioblastoma
Signaling pathways initiated from numerous growth factor
receptors are known to play pivotal roles in developmental
and tumor-mediated angiogenesis. In this review, we focus
on three signaling pathways with a proven role in vascular
biology and/or tumor angiogenesis that are currently being
explored in clinical trials (Table 1) or represent major
pharmaceutical targets that are under intense scrutiny. In
addition to these angiogenic factors, further angiogenic
signaling pathways are provided by axon guidance mole-
cules that are known to play a role in both vascular and
neuronal patterning (for recent review see [1, 37]. How-
ever, due to their prominent role in nervous system
development and homeostasis it appears questionable
whether these molecules will become targets for anti-
angiogenic glioma therapy (see below and [115]).
VEGF signaling
VEGF is the principal angiogenesis factor in both embry-
onic development and tumor growth (for review see [38]).
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to embryonic lethality in the mouse due to severe defects in
the developing vascular system [14, 42, 43, 133]. A role for
VEGF in cerebral vascularization is illustrated by analysis
of the conditional deletion of VEGF in the nervous system
using a Nestin-cre/VEGF ﬂox binary transgenic mouse to
speciﬁcally delete VEGF in all Nestin-expressing cells.
Mice carrying this deletion have a severe phenotype where
the primitive perineural vascular plexus is able to develop,
but vascular sprouts do not penetrate into the primitive
Table 1 Current clinical trials targeting the VEGF/VEGFR or Ang/Tie2 signaling pathways in glioblastoma
Compound Target Combination Phase NCT number Status Company and/or trial center
Aﬂibercept VEGF Temozolomide
Radiation
I NCT00650923 Active Sidney Kimmel
Comprehensive Cancer
Center
II NCT00369590 Completed Sidney Kimmel
Comprehensive Cancer
Center
AZD2171 (Cediranib
Maleate, Recentin)
VEGF Bevacizumab I NCT00458731 Active M.D. Anderson Cancer
Center
Bevacizumab VEGF Temozolomide II NCT00590681 Active Genentech
Erlotinib II NCT00671970 Active Genentech
Irinotecan Voronistat I NCT00762255 Active Merck
Radiation
Temozolomide
II NCT01478321 Active Northwestern University
Temozolomide II NCT01013285 Active UCLA
II NCT00271609 Active National Cancer Institute
Temsirolimus II NCT00800917 Completed Roch/Pﬁzer
Cetuximab Irinotecan II NCT00463073 Completed
Bevacizumab VEGF Irinotecan II NCT00463203 Completed
TPI287 I/II NCT01582152 Recruiting Archer Biosciences, Inc.
Voronistat I/II NCT01266031 Recruiting Genentech
Temozolomide II NCT01149850 Recruiting Genentech
Radiosurgery I/II NCT01086345 Recruiting Case Comprehensive
Cancer Center
Lomustine II NCT01067469 Recruiting M.D. Anderson Cancer
Center
Stereotactic
Radiotherapy
I NCT01392209 Recruiting Genentech
Lenalidomide I NCT01183663 Recruiting M.D. Anderson Cancer
Center
Rindopepimut/GM-CSF II NCT01498328 Recruiting Celldex Therapeutics
Irinotecan II NCT00393094 Terminated National Cancer Institute
AEE788 VEGFR, EGFR/
ErbB2
I/II NCT00116376 Completed Novartis
BIBF 1120 VEGFR, PDGFR,
FGFR
II NCT01251484 Active Boehringer Ingelheim
Pharmaceuticals
University of
Copenhagen
Pazopanib VEGFR-1/2/3,
PDGFR, c-Kit
Lapatinib II NCT00350727 Completed GlaxoSmithKline
AMG 386 (Trebanabnib) Ang-1/2 Bevacizumab I/II NCT01290263 Suspended Amgen
I NCT01538095 Recruiting National Cancer Institute
Bevacizumab II NCT01609790 Recruiting National Cancer Institute
(NCI)
PF- 04856884 (CVX-060) Ang-2 II NCT01225510 Withdrawn Pﬁzer
Ang Angiopoietin, VEGF vascular endothelial growth factor, VEGFR vascular endothelial growth factor receptor
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123avascular neuroectoderm. These mice have an avascular
brain that causes microcephaly and massive periventricular
apoptosis [116].
In GBM, VEGF is highly up-regulated, in particular in
perinecrotic pseudopalisading cells [113, 134]. A major
driving force of VEGF expression in GBM appears to be
tumor hypoxia since VEGF and other hypoxia-inducible
genes such as HIF-1 alpha and LDH are expressed in the
same cell type [156]. Data derived from The Cancer Gen-
ome Atlas (TCGA) (http://cancergenome.nih.gov) suggest
that in GBM the entire VEGF/VEGF receptor system
is predominantly orchestrated by the up-regulation of
VEGF; however, the VEGF receptors-1, -2 and -3 are also
up-regulated in the tumor vasculature. The vast majority of
clinical trials that target tumor angiogenesis use drugs that
target the VEGF signaling pathway, either by blocking
VEGF or by interfering with VEGFR-2 signaling (see
Table 1 and for review [100]). The most advanced VEGF-
speciﬁc drug currently on the market is bevacizumab,
a monoclonal antibody that blocks VEGF function.
Bevacizumab is routinely used in combination with che-
motherapy (e.g., irinotecan) for the treatment of recurrent
glioblastoma [19, 142, 147]. Unfortunately, several recent
clinical reports suggest that anti-VEGF treatment may in
fact promote a pro-migratory cellular tumor phenotype in
patients with recurrent glioblastoma (for example [24,
102]).Importantly,these clinical observations are supported
by several pre-clinical studies that in principle show that
anti-VEGF treatment in mice or rats promotes a pro-inva-
sive phenotype and may even increase tumor metastasis [35,
68, 107]. A possible explanation for this phenomenon,
which represents a major challenge and clinical drawback,
might be the induction of hypoxia and up-regulation of
hypoxia-inducible genes via the HIF-1 alpha pathway
[117]. Indeed, it has been suggested that hypoxia-mediated
migration of tumor cells is responsible for the development
of ‘‘pseudopalisading’’ glioma cells surrounding necroses, a
histological hallmark of glioblastoma [10]. As such, these
cells may represent glioma cells that are hypoxic and ‘‘try to
escape’’ from a low oxygen microenvironment [110, 114].
The molecular mechanisms underlying this event are only
partly understood. The protooncogene c-met, for example,
has been shown to be up-regulated by hypoxia and to trigger
invasion [9, 36, 108]. Recently, it has been suggested that
c-met is activated in GBM upon bevacizumab treatment in a
VEGFR-2 and phosphotyrosine phosphatase (PTP1B)-
dependent manner. In this scenario, bevacizumab-induced
depletion of VEGF reduces PTP1B activity and promotes
c-met phosphorylation. This mechanism may therefore
account at least in part for the observed therapy-induced
switch to a pro-migratory phenotype after bevacizumab
treatment [20, 92]. However, this putative mechanism
requires the co-expression of c-met together with VEGFR-2
on glioma cells in vivo. Whereas VEGFR-2 can be readily
detected in glioma cell lines in vitro, most studies suggest
that in both murine and human glioma specimens in vivo
expression of VEGFR-2 is mainly conﬁned to vascular
endothelial cells [51, 52, 77, 87, 112–114, 136], and
potentially to a subset of cancer stem-like cells [49]. As
such, it remains currently unclear whether the mechanism of
bevacizumab-induced migrationofglioma cellsasproposed
by Lu et al. is of relevance in human glioblastoma in vivo.
Tie2/Angiopoietin signaling
Pharmacological interference of the Tie2/Angiopoietin
signaling pathway has received considerable attention
recently (for review see [17, 58]). Several pre-clinical
studies have shown that modulation of this pathway leads
to alterations in vascular morphology and inhibition of
tumor growth. Several types of angiopoietin inhibitors are
now in phase I–III clinical trials (Table 1). The Tie2
receptor tyrosine kinase is expressed in endothelial cells
and a subset of hematopoietic cells during development
[34]. Similar to VEGF receptors, Tie2 is critical for normal
vascular development [33]; however, in contrast to VEGF
receptors that are down-regulated after embryonic angio-
genesis has ceased, Tie2 appears to be constitutively
expressed and phosphorylated in the adult vasculature
[150]. This constitutive expression and activation suggests
that signaling via Tie2 is important for the homeostasis of
the mature vasculature (Fig. 3). Indeed, Tie2 signaling
promotes stable vessels that are covered by pericytes. Tie2
is bound by three different ligands that engage the same
binding site on the receptor. Angiopoietin-1 (Ang-1) and
Angiopoietin-2 (Ang-2) are the ﬁrst ligands to be discov-
ered and are the best studied, whereas the function of Ang-
4 is less understood. These ligands are thought to bind to
Tie2 with roughly similar afﬁnities and cause receptor
activation [144]. In addition to Tie2, integrins serve as
receptors for angiopoietins. A major observation has been
that Ang-1 acts as a stimulating ligand for the Tie2 RTK
that leads to receptor phosphorylation, whereas Ang-2
inhibits Tie2 phosphorylation, even in the presence of Ang-
1[ 64, 94]. Ang-1 can ‘‘seal’’ vessels in vivo and decrease
vascular permeability [61]. Interestingly, the major regu-
lator of the entire Tie2/Angiopoietin signaling pathway
appears to be Ang-2. TCGA data for glioblastoma reveal
that Ang-2 is up-regulated to a much higher extent than
Ang-1, suggesting that Tie2 signaling is blocked in glio-
blastoma (http://cancergenome.nih.gov). The consequences
of blocking Tie2 signaling in vivo, as evidenced by several
pre-clinical studies, appears to be a shift towards an
immature vasculature, whereas Ang-1 appears to ‘‘nor-
malize’’ the vasculature (see below). In addition to an
impact on angiogenesis, Ang-2 was shown to mediate a
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inﬂammatory response to stimuli such as TNF-a was
greatly diminished when compared to controls [39]. Vice
versa, in mice engineered to express an inducible form of
Ang-2 in the vasculature, myeloid cells increased signiﬁ-
cantly over time in almost all organs, even without any
pathological stimulus [128]. These ﬁndings suggest that
Ang-2 on its own is able to orchestrate an inﬂammatory
response by speciﬁcally recruiting myeloid cells—and
leaving lymphocytes behind (reviewed in [69]). Moreover,
since Ang-2 is highly expressed in glioblastoma vessels
[141], Ang-2 up-regulation may also account—at least in
part—for the attraction of myeloid cells of the monocyte/
macrophage lineage to human gliomas. As such, inhibiting
Ang-2 may have at least two different effects on tumor
growth: (1) a shift of balance towards mature vessels (e.g.,
vascular normalization) and subsequent decrease of intra-
tumoral hypoxia (2) inhibition of monocyte/macrophage
recruitment to tumors [57, 59, 86, 97].
Notch signaling pathway
The Notch signaling pathway plays an important role in
organ development and recently has also received consid-
erable attention in the vascular biology ﬁeld recently (for
review see [8, 78, 122]). Of the four Notch receptors,
Notch1 and Notch4 are expressed on endothelial cells but
Notch1 appears to be the most important for developmental
angiogenesis. Similar to their receptors, Notch ligands are
membrane-bound. Delta-like ligand4 (Dll4) appears to be
the most important Notch ligand for stimulating angio-
genesis, whereas another ligand, Jagged1, negatively
regulates angiogenesis by competing with Dll4 [4, 78].
Notch in concert with VEGF signaling appears to be
instrumental in the tip cell versus stalk cell fate decision
that is essential for the initiation of sprouting angiogenesis
(see Fig. 2). VEGF-A induces signaling in VEGFR-2
and -3, which are expressed in the tip cells leading to
up-regulation of Dll4 and subsequent activation of Notch
signaling in adjacent endothelial stalk cells. This signaling
cascade places the Notch signaling pathway downstream of
VEGFR-2 and R-3 signaling in endothelial cells. Once
activated, Notch signaling can ultimately provide negative
feedback on VEGFR signaling by up-regulating VEGFR-1
but inhibiting VEGFR-2 and R-3 expression in stalk cells,
this signaling circuit provides a way for regulating tip
versus stalk cell fate decisions [5]. The up-regulation of
VEGFR-1, which acts as a decoy receptor, further con-
tributes to the maintenance of the VEGF gradient. Blocking
of Dll4–Notch interaction leads to hypervascular tumors
that are nevertheless inhibited in their growth. This phe-
nomenon has been entitled the ‘‘delta-paradox’’ and is
probably based on the excessive production of non-func-
tional vessels (e.g., tumor vessel abnormalization) [78].
Since Dll4 has been primarily detected in glioblastoma
vasculature and not in glioma cells [65], targeting Dll4 by
neutralizing antibodies is considered a potential anti-
angiogenic tumor therapy. However, safety concerns have
been arisen since it has been reported that in preclinical
models, chronic Dll4 blockade abnormally activates
endothelial cells and causes vascular neoplasms [152].
The concept of vascular normalization
The concept of ‘‘vascular normalization’’ has been intro-
duced by Jain [60]. This concept states that anti-angiogenic
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Fig. 3 Involvement of Angiopoietins during vascular regression.
a Vascular regression occurs under both, pathological and physio-
logical settings and is characterized by local pericyte loss (turquois)
and the disappearance of endothelial cells, leaving an empty basement
membrane sleeve (‘‘ghost vessels’’/blue). b During vascular homeo-
stasis shear stress is inducing Kruppel-like factor 2 (KLF2), a
negative regulator of Angiopoietin-2 (Ang-2). Furthermore, Ang-1
(black) is secreted by mural cells into the extra cellular matrix (ECM/
blue) and can then bind to endothelial expressed Tie2 (green) that will
translocate to the cell–cell junctions upon Ang-1 binding forming
homodimers in trans. Tie2 signaling further up-regulates KLF2 and
stabilizes junctional molecules such as VE-cadherin (yellow). During
vascular regression the occlusion of vessels leads to disturbed and
reduced blood ﬂow leading to KLF2 down-regulation. Ang-2
(orange) in turn becomes upregulated and triggers the dissociation
of pericytes, the degradation of the basement membrane by inducing
matrix metalloproteases (MMPs) and interferes with endothelial cell
integrity
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123(e.g., Bevacizumab) treatment merely affects the immature
vasculature and leaves the mature vessels unaltered.
Indeed, it has been shown that VEGF withdrawal leads to
selective ablation of immature blood vessels [6]. As such, a
‘‘normalized’’ vasculature results as a consequence of anti-
VEGF treatment, leading to increased perfusion of the
tumor and subsequent increase of oxygenation. Vascular
normalization is thought to interrupt the vicious circle that
is driven by hypoxia and that leads to up-regulation of
VEGF, resulting in the growth of immature—partly un-
perfused—vessels and a subsequent increase in tumor
hypoxia [23]. Some researchers believe that vessel nor-
malization followed by cytotoxic chemotherapy and/or
radiotherapy should be the ultimate goal of any anti-
angiogenic therapy [62]. Indeed, in an experimental glioma
model, intratumoral vascular normalization restored blood–
brain barrier properties by suppressing edema formation
[118] and a clinical study showed increased blood perfu-
sion in GBM after anti-angiogenic therapy [138]. In order
to achieve vascular normalization, several potential targets
beside anti-VEGF therapy have been identiﬁed that include
(1) Tie2/Angiopoietin signaling (see above), (2) prolylhy-
droxylases, which are upstream of the HIF-signaling
pathway [23], (3) blockade of the VEGF receptor-1 ligand
placenta growth factor (PlGF) [40], (4) blocking of TGF-ß
signaling [31] and (5) increase of vascular wnt/ß-catenin
signaling [118].
The role of myeloid cells in tumor angiogenesis
Current studies suggest that inﬁltrating myeloid cells con-
tribute signiﬁcantly to tumor angiogenesis, presumably by
secreting pro-angiogenic factors including VEGF, stromal-
derived factor-1 (SDF-1) and others (Fig. 4, for review see
[47, 101]). Grunewald et al. [48] have shown that myeloid
cells are (1) recruited to tumors, (2) ‘‘educated’’ by the
tumor microenvironment and (3) support tumor growth by
secretion of SDF-1. In another study, chimeric mice were
generated by transplanting bone marrow from VEGFR-1
signaling deﬁcient mice into lethally irradiated wild-type
mice. When Gl261 glioma cells were transplanted intra-
cranially into these mice, tumor growth was signiﬁcantly
inhibited when compared to mice harboring a normal bone
marrow. Subsequent studies showed that VEGFR-1 sig-
naling deﬁcient bone marrow chimeras displayed a defect
in monocyte migration leading to signiﬁcant lower amount
of myeloid cells in the tumor tissue [67]. In a preclinical
study, myeloid cell inﬁltration has been shown to be
associated with tumor progression after anti-angiogenic
therapy [109]. In a clinical study, a decrease in the number
of VEGFR-1 ? monocytes in the blood correlated with
improved response after bevacizumab treatment [25]. Most
of the myeloid cells that support tumor growth through the
stimulation of angiogenesis appear to be monocytes/mac-
rophages with M2 polarity (TAMs, tumor-associated
macrophages) [135]. In contrast, bone marrow-derived
non-hematopoietic mesenchymal stem cells may in fact
suppress glioma growth through the inhibition of angio-
genesis [54]. Interestingly, one distinct subtype of
monocytes with particular importance for tumor angio-
genesis and immunosuppression seems to be Tie2-
expressing monocytes (TEMs) [28]. TEMs represent a
subset of circulating blood monocytes that are recruited
from the circulation into tumors and locally support tumor
growth in a paracrine manner [88]. Although the number of
TEMs within a tumor appears relatively small (e.g.,\10 %
of inﬁltrating monocytes express Tie2) [21], loss of func-
tion studies using suicide gene approaches have shown that
the speciﬁc depletion of TEMs is able to block tumor
angiogenesis and tumor growth [29]. The number of inﬁl-
trating macrophages has been shown to be of prognostic
relevance in breast cancer [85], rectal cancer [132], classic
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Fig. 4 The role of tumor-associated macrophages (TAMs) during
tumor angiogenesis. TAMs (blue) can promote tumor growth in at
least two different ways: 1. TAMs, actively suppress the hosts
immune response to tumors by secretion of immunosuppressive
mediators, such as IL-6 and IL-10. 2. TAMs are a signiﬁcant source of
angiogenic factors (e.g., FGF2, MMPs, VEGF) that promote tumor
neovessel formation and thereby contribute to malignant progression.
Macrophages are thought to participate in and support the process of
anastomosis, the fusion of two vascular sprouts to establish a direct
connection. During this setting, macrophages (blue) can be found
intimately associated with endothelial tip cells (red). It is hypothe-
sized that their recruitment to sites of vessel fusion is driven by tip
cell secreted Ang-2 (orange) that can attract macrophages in a Tie2-
dependent or Tie-2 independent pathway, with the latter being
mediated by beta2-integrins
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123Hodgkin’s lymphoma [139], adenocarcinoma of the lung
[157] and hepatocellular carcinoma [27, 96]. Therefore,
both TEMs and TAMs clearly have evolved as novel tar-
gets for anti-angiogenic cancer therapy [26, 66].
Future prospects for anti-angiogenic therapy
The ﬁrst speciﬁc anti-angiogenic drug that received FDA
approval in 2004 was bevacizumab, a neutralizing mono-
clonal antibody to VEGF. Bevacizumab is widely used in
different types of cancer and signiﬁcantly inhibits tumor
growth in many cancer types (see Table 1 for current anti-
angiogenesis trials in glioblastoma). However, drugs that
interfere with the function of the vascular system may also
cause—sometimes severe—undesired effects [3, 84].
VEGFR-2 is not only expressed on endothelial cells but also
on hemangioblasts and angioblasts [121] and in the nervous
system (see below). Documented undesired effects of bev-
acizumab therapy include hypertension, induction of
bleeding disorders and deep venous thrombosis [100, 103].
Chronic inhibition of the Notch pathway by Dll4 blockade
usinginhibitoryantibodiesmayevenleadtotheinductionof
vascular neoplasms [152]. In addition, many vascular
growth factors have been shown to be involved in the
development and homeostasis of the nervous system by
directly interacting with neurons (for review see [37, 115,
124, 125]). VEGF, for example, acts as a survival factor for
neurons in vitro and in vivo and promotes neurogenesis,
mostlikelythrough interactionwith VEGFR-2 expressedon
neurons[13,22,63,127,149,153].PartialdeletionofVEGF
in mice leads to loss of motoneurons and subsequently to a
phenotype that highly resembles amyotrophic lateral scle-
rosis (ALS) in humans [106]. Indeed, polymorphisms in the
vegfa gene are associated with a higher risk to develop ALS
in humans [83] and delivery of recombinant VEGF has been
used successfully to protect motoneurons in a rat model of
ALS [140]. Currently, intracerebroventricular delivered
VEGF is in clinical phase I/II trial for patients with ALS.
Further, in line with a direct effect of VEGF on the nervous
system, anti-VEGF receptor treatment has been reported to
lead a painful sensory neuropathy [146].
In addition to the above-mentioned adverse effects of
anti-VEGF treatment, pre-clinical and clinical reports sug-
gest that cancer cells may develop resistance to anti-
angiogenic therapy by different mechanisms that include
(1) switch to a pro-migratory phenotype, (2) up-regulation
of other pro-angiogenic molecules [151] and (3) the
increased recruitment of myeloid cells that support tumor
growth (reviewed in [7, 66, 129]). As such, novel therapies
are currently under development in both academia and
pharmaceutical companies that include (1) novel VEGF
inhibitors such as the VEGF trap [46, 55], (2) drugs that
target the Tie2/Angiopoietin signaling pathway (reviewed
in [17, 58]), (3) double inhibition of VEGF and angio-
poietins [12, 18, 73], (4) double inhibition of VEGF and
c-met [130, 154], (5) inhibition of PlGF [30, 40] and (6)
drugs that block myeloid cell recruitment and/or their
polarization [91], among others. However, it has been
suggested that intratumoral vessel are heterogenous and
that, for example, VEGF-dependent and -independent ves-
sels may co-exist within a given tumor [137]. These
observations speak in favor of a multi-modal therapy that
may combine different types of anti-angiogenic therapy or
anti-angiogenic therapy together with cytotoxic therapy.
The integrin inhibitor cilengitide, for example, targets both
tumor cells and the vasculature [105], and is now in phase
III clinical trial for glioblastoma patients [79, 126]. In our
personal view, targeting the Tie2 signaling pathway by
blocking Ang-2 or stimulating Ang-1 (or both simulta-
neously) may be particularly promising since three
mechanisms of tumor angiogenesis may be targeted simi-
larly: (1) sprouting angiogenesis and (2) myeloid cell
inﬁltration may be blocked, whereas (3) vascular normali-
zation will be enhanced [17, 58]. Further, reported side
effects of Ang-2 blocking appear to be sparse compared to
other anti-angiogenic therapies employed [53, 82]. How-
ever, this has to be proven further in the clinical trials that
are currently under way. It may also be necessary to stratify
patients so that those that have a shift in the Ang-1/Ang-2
balance or other angiogenic factors are identiﬁed and the
appropriate therapy initiated. For example, the monitoring
of expression patterns of angiogenesis factors and their
receptor in the tumor biopsy or the evaluation of biomarkers
in the serum or cerebrospinal ﬂuid of patients may provide
useful indicators of a tumor’s susceptibility to a particular
targeted therapy [100]. Promising biomarkers that may
indicate therapy responsiveness in anti-angiogenic therapy
include serum Ang-2 levels and the number of circulating
VEGFR-1 ? monocytes [25, 45, 90]. It will be exciting to
watch whether any of the newly developed therapies will be
able to signiﬁcantly affect survival of brain cancer patients.
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